These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37448364)

  • 1. STAT3 Signaling Axis and Tamoxifen in Breast Cancer: A Promising Target for Treatment Resistance.
    Zamanian MY; Golmohammadi M; Alalak A; Kamiab Z; Obaid R; Ramírez-Coronel AA; Hjazi A; Abosaooda M; Mustafa Y; Heidari M; Verma A; Nazari Y; Bazmandegan G
    Anticancer Agents Med Chem; 2023; 23(16):1819-1828. PubMed ID: 37448364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
    Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer.
    Fu H; Han X; Guo W; Zhao X; Yu C; Zhao W; Feng S; Wang J; Zhang Z; Lei K; Li M; Wang T
    Sci Rep; 2024 Oct; 14(1):22988. PubMed ID: 39362925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
    Xing J; Li J; Fu L; Gai J; Guan J; Li Q
    Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
    Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
    Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells.
    Yi EH; Lee CS; Lee JK; Lee YJ; Shin MK; Cho CH; Kang KW; Lee JW; Han W; Noh DY; Kim YN; Cho IH; Ye SK
    Mol Cancer Res; 2013 Jan; 11(1):31-42. PubMed ID: 23074171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
    Ishii Y; Waxman S; Germain D
    Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoleamine 2,3-dioxygenase 1 regulates breast cancer tamoxifen resistance through interleukin-6/signal transducer and activator of transcription.
    Zhao X; Jiang Y; Xu M; Hu J; Feng N; Deng H; Lu C; Huang T
    Toxicol Appl Pharmacol; 2022 Apr; 440():115921. PubMed ID: 35157906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting autophagy with tamoxifen in breast cancer: From molecular mechanisms to targeted therapy.
    Zamanian MY; Golmohammadi M; Nili-Ahmadabadi A; Alameri AA; Al-Hassan M; Alshahrani SH; Hasan MS; Ramírez-Coronel AA; Qasim QA; Heidari M; Verma A
    Fundam Clin Pharmacol; 2023 Dec; 37(6):1092-1108. PubMed ID: 37402635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
    Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
    Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
    Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
    J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin.
    Yang Y; Zhao J; Mao Y; Lin G; Li F; Jiang Z
    Breast Cancer Res Treat; 2020 Dec; 184(3):699-710. PubMed ID: 32914356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
    Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
    Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.
    Zhao W; Ma J; Zhang Q; Zhang H; Ma W; Li S; Piao Y; Zhao S; Dai S; Tang D
    Cell Biol Int; 2024 Apr; 48(4):496-509. PubMed ID: 38225685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.
    Madden SF; Cremona M; Farrelly AM; Low WH; McBryan J
    Cancer Gene Ther; 2023 Feb; 30(2):324-334. PubMed ID: 36266450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.